{"id":"NCT00887822","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer","officialTitle":"A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2011-05","completion":"2014-08","firstPosted":"2009-04-24","resultsPosted":"2017-03-01","lastUpdate":"2017-03-01"},"enrollment":202,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]}],"arms":[{"label":"Bevacizumab, Capecitabine and Cisplatin","type":"EXPERIMENTAL"},{"label":"Placebo, Capecitabine and Cisplatin","type":"PLACEBO_COMPARATOR"}],"summary":"This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer. Participants will be randomized to one of two treatment groups Bevacizumab + Capecitabine/Cisplatin (experimental arm) or Placebo + Capecitabine/Cisplatin (control arm).","primaryOutcome":{"measure":"Percentage of Participants With Event (Death)","timeFrame":"From randomization until death (up to 34 months)","effectByArm":[{"arm":"Bevacizumab, Capecitabine and Cisplatin","deltaMin":77,"sd":null},{"arm":"Placebo, Capecitabine and Cisplatin","deltaMin":75.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":14,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":100},"commonTop":["Nausea","Vomiting","Neutropenia","Decreased appetite","Leukopenia"]}}